Moderna has submitted a conditional marketing approval (CMA) request to the European Medicines Agency for the use of its Covid-19 vaccine among adolescents. The submission comes after a Phase II/III study of the mRNA-1273 vaccine in adolescents aged between 12 and 18 years in the US. In May, the company announced that its Phase II/III TeenCOVE study of Moderna’s vaccine in adolescents met its primary immunogenicity endpoint.
The Ministry of Health of the Republic of Congo has approved the Russian-produced single-dose Sputnik Light vaccine to fight Covid-19. Sputnik Light is the first component of the Sputnik V vaccine and has shown 79.4% efficacy according to analysed data from 28 days after the administration of a single jab. The data was drawn from Russians vaccinated with a single jab and having not yet received the second, the Russian Direct Investment Fund said.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
